AGMB
Income statement / Annual
Last year (2024), AgomAb Therapeutics NV's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, AgomAb Therapeutics NV's net income was -$46.27 M.
See AgomAb Therapeutics NV,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$39.31 M
|
$26.31 M
|
$19.42 M
|
| General & Administrative Expenses |
$9.82 M
|
$6.00 M
|
$4.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.82 M
|
$6.00 M
|
$4.49 M
|
| Other Expenses |
-$1.11 M
|
-$1.12 M
|
-$1.28 M
|
| Operating Expenses |
$48.02 M
|
$31.19 M
|
$22.63 M
|
| Cost And Expenses |
$48.02 M
|
$31.19 M
|
$22.63 M
|
| Interest Income |
$1.22 M
|
$245.00 K
|
$71.00 K
|
| Interest Expense |
$67.00 K
|
$31.00 K
|
$45.00 K
|
| Depreciation & Amortization |
$311.00 K
|
$99.00 K
|
$23.00 K
|
| EBITDA |
-$45.89 M |
-$11.88 M |
-$10.74 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.76 M
|
$19.18 M
|
$11.83 M
|
| Income Before Tax |
-$46.26 M
|
-$12.01 M
|
-$10.81 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$4.00 K
|
-$619.00 K
|
-$2.66 M
|
| Net Income |
-$46.27 M
|
-$11.39 M
|
-$8.14 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.26 |
-0.31 |
-0.22 |
| EPS Diluted |
-1.26 |
-0.31 |
-0.22 |
| Weighted Average Shares Out |
$36.24 M
|
$36.24 M
|
$36.24 M
|
| Weighted Average Shares Out Diluted |
$36.24 M
|
$36.24 M
|
$36.24 M
|
| Link |
|
|
|
